Tag: Nominations
-
Finalists: JP Morgan Life Sciences Innovation Summit
Cellestial Health has been named as one of the 10 global finalists in the Second Annual Life Sciences Innovation Summit organised by J.P. Morgan Asset Management’s Life Sciences Private Capital and King Abdullah International Medical Research Center (كيمارك KAIMRC), alongside EpiBone, Inc., FimmCyte Therapeutics, Genethon NewCo, NanoPalm | نانو بالم, Neurenati Therapeutics, Rinri Therapeutics, Script Biosciences,…
-
Winning Pitch at Founders Live Cambridge
Friends, There are around 3 billion people affected by neurological conditions in the world, of which approximately 10 million have Parkinson’s. There is no cure, and most new treatments for Parkinson’s aim to protect brain cells called neurones. However, did you know that neurones only represent around half of our brains?So, can we hope to…
-
#21toWatch 2025: Winners!
What an incredible honour to be acknowledged as one of the most innovative companies in the East of England this year at #21toWatch campaign ✨ Supported by the cofinitive team including Faye Holland, Gemma Dorling, and Carole Aye Maung, and meticulously judged by Christine Martin, Chris Ellis, Thomas Hughes, and Jo Słota-Newson, the event on…
-
#21toWatch 2025: Proud to be Short-Listed!
Friends, Cellestial Health is honoured to be shortlisted in the prestigious #21toWatch Companies list – among other impressive contestants such as Lucy Jung, co-founder of Charco Neurotech, and Jonathan Fisher. Both of these inventors are working on wearable devices to reduce motor symptoms of Parkinson’s. At the same time, Arko Paul at Oltera is designing…
-
#21toWatch 2025: Proud to be Listed
Cellestial team are grateful for the nomination for the prestigious #21toWatch Award showcasing leaders across Cambridge and the East of England – we have made it to the Companies longlist. We are looking forward to seeing all the amazing people, companies, and things showcased by the campaign. Find out more: https://www.21towatch.com